Cancer
Conditions
Brief summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.
Detailed description
The aim of this study was to explore the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in patients with solid tumors or lymphoma.
Interventions
68Ga-NODAGA-SNA006 PET/CT: after intravenous injection of 0.05 mCi/kg body weight of quality-controlled 68Ga-NODAGA-SNA006, an integrated PET/CT scanner (Biograph mCT; Siemens, Germany) will be applied.
Sponsors
First Hospital of China Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Participants who were diagnosed with malignant tumors; 2. Patients are between 18 and 80 years of age are between 18 and 80 years of age.
Exclusion criteria
1. Participants who were unable or unwilling to provide written informed consent. 2. Participants who were unable to successfully complete the examination and are forced to abort the test in the middle of the test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of 68Ga-NODAGA-SNA006-emergent Adverse Events | 3 YEAR | Through PET/CT, Visual analysis was positive, or the SUVmax was more than the mediastinum |
| Biodistribution of 68Ga-NODAGA-SNA006 | 3 YEAR | Through PET/CT analysis, SUVmax and SUVmean of the organs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation analysis of 68Ga-NODAGA-SNA006 uptake and tumor immune phenotype | 3 YEAR | Correlation coefficients (r²) between SUVmax and SUVmean measured by PET/CT and immunophenotypes |
Countries
China
Outcome results
None listed